652 related articles for article (PubMed ID: 9533549)
41. Different expression of lysosome-associated membrane protein-1 in human melanomas and benign melanocytic lesions.
Kuźbicki L; Gajo B; Chwirot BW
Melanoma Res; 2006 Jun; 16(3):235-43. PubMed ID: 16718270
[TBL] [Abstract][Full Text] [Related]
42. The effect of antisense tyrosinase-related protein 1 on melanocytes and malignant melanoma cells.
Li CY; Gao TW; Wang G; Han ZY; Shen Z; Li TH; Liu YF
Br J Dermatol; 2004 Jun; 150(6):1081-90. PubMed ID: 15214892
[TBL] [Abstract][Full Text] [Related]
43. Desensitization of melanoma cells to autocrine TGF-beta isoforms.
Krasagakis K; Krüger-Krasagakes S; Fimmel S; Eberle J; Thölke D; von der Ohe M; Mansmann U; Orfanos CE
J Cell Physiol; 1999 Feb; 178(2):179-87. PubMed ID: 10048582
[TBL] [Abstract][Full Text] [Related]
44. The 92-kDa gelatinase B is expressed by advanced stage melanoma cells: suppression by somatic cell hybridization with early stage melanoma cells.
MacDougall JR; Bani MR; Lin Y; Rak J; Kerbel RS
Cancer Res; 1995 Sep; 55(18):4174-81. PubMed ID: 7664294
[TBL] [Abstract][Full Text] [Related]
45. Melanoma inhibitor of apoptosis protein is expressed differentially in melanoma and melanocytic naevus, but similarly in primary and metastatic melanomas.
Gong J; Chen N; Zhou Q; Yang B; Wang Y; Wang X
J Clin Pathol; 2005 Oct; 58(10):1081-5. PubMed ID: 16189155
[TBL] [Abstract][Full Text] [Related]
46. Expression of integrin alpha5beta1 and MMPs associated with epithelioid morphology and malignancy of uveal melanoma.
Béliveau A; Bérubé M; Rousseau A; Pelletier G; Guérin SL
Invest Ophthalmol Vis Sci; 2000 Jul; 41(8):2363-72. PubMed ID: 10892885
[TBL] [Abstract][Full Text] [Related]
47. ELK and LERK-2 in developing kidney and microvascular endothelial assembly.
Daniel TO; Stein E; Cerretti DP; St John PL; Robert B; Abrahamson DR
Kidney Int Suppl; 1996 Dec; 57():S73-81. PubMed ID: 8941926
[TBL] [Abstract][Full Text] [Related]
48. Cytokeratin expression in malignant melanoma: potential application of in-situ hybridization analysis of mRNA.
Chen N; Gong J; Chen X; Xu M; Huang Y; Wang L; Geng N; Zhou Q
Melanoma Res; 2009 Apr; 19(2):87-93. PubMed ID: 19190520
[TBL] [Abstract][Full Text] [Related]
49. Expression of nm23-H1 in uveal melanoma.
Bakalian S; Marshall JC; Faingold D; Logan P; Antecka E; Burnier MN
Melanoma Res; 2007 Oct; 17(5):284-90. PubMed ID: 17885583
[TBL] [Abstract][Full Text] [Related]
50. Micro-anatomy related antigen expression in melanocytic lesions.
Meije CB; Mooi WJ; Le Poole IC; Van Muijen GN; Das PK
J Pathol; 2000 Apr; 190(5):572-8. PubMed ID: 10727983
[TBL] [Abstract][Full Text] [Related]
51. Heterogeneous expression of immunotherapy candidate proteins gp100, MART-1, and tyrosinase in human melanoma cell lines and in human melanocytic lesions.
de Vries TJ; Fourkour A; Wobbes T; Verkroost G; Ruiter DJ; van Muijen GN
Cancer Res; 1997 Aug; 57(15):3223-9. PubMed ID: 9242453
[TBL] [Abstract][Full Text] [Related]
52. Expression of calcyclin in human melanocytic lesions.
Weterman MA; van Muijen GN; Bloemers HP; Ruiter DJ
Cancer Res; 1993 Dec; 53(24):6061-6. PubMed ID: 8261423
[TBL] [Abstract][Full Text] [Related]
53. Expression of microtubule-associated protein 2 in benign and malignant melanocytes: implications for differentiation and progression of cutaneous melanoma.
Fang D; Hallman J; Sangha N; Kute TE; Hammarback JA; White WL; Setaluri V
Am J Pathol; 2001 Jun; 158(6):2107-15. PubMed ID: 11395388
[TBL] [Abstract][Full Text] [Related]
54. Role of interleukin (IL)-2 and IL-15 in the tumour progression of a melanoma cell line MELP, derived from an IL-2 progressor patient.
Doucet C; Meazza R; Pottin-Clemenceau C; Scudeletti M; Brouty-Boye D; Ferrini S; Alileche A; Taoufik Y; Jasmin C; Azzarone B; Indiveri F
Melanoma Res; 1997 Aug; 7 Suppl 2():S7-17. PubMed ID: 9578412
[TBL] [Abstract][Full Text] [Related]
55. Cdc7 expression in melanomas, Spitz tumors and melanocytic nevi.
Clarke LE; Fountaine TJ; Hennessy J; Bruggeman RD; Clarke JT; Mauger DT; Helm KF
J Cutan Pathol; 2009 Apr; 36(4):433-8. PubMed ID: 19278428
[TBL] [Abstract][Full Text] [Related]
56. Identification of the human PHLDA1/TDAG51 gene: down-regulation in metastatic melanoma contributes to apoptosis resistance and growth deregulation.
Neef R; Kuske MA; Pröls E; Johnson JP
Cancer Res; 2002 Oct; 62(20):5920-9. PubMed ID: 12384558
[TBL] [Abstract][Full Text] [Related]
57. Immunoreactivity with the anti-MAGE antibody 57B in malignant melanoma: frequency of expression and correlation with prognostic parameters.
Busam KJ; Iversen K; Berwick M; Spagnoli GC; Old LJ; Jungbluth AA
Mod Pathol; 2000 Apr; 13(4):459-65. PubMed ID: 10786815
[TBL] [Abstract][Full Text] [Related]
58. Different expression patterns of p27 and p57 proteins in benign and malignant melanocytic neoplasms and in cultured human melanocytes.
Curry JL; Richards HW; Huttenbach YT; Medrano EE; Reed JA
J Cutan Pathol; 2009 Feb; 36(2):197-205. PubMed ID: 18647205
[TBL] [Abstract][Full Text] [Related]
59. Melanoma-inhibiting activity (MIA/CD-RAP) is expressed in a variety of malignant tumors of mainly neuroectodermal origin.
Hau P; Apfel R; Wiese P; Tschertner I; Blesch A; Bogdahn U
Anticancer Res; 2002; 22(2A):577-83. PubMed ID: 12014625
[TBL] [Abstract][Full Text] [Related]
60. Tumor progression in melanoma: the biology of epidermal melanocytes in vitro.
Mancianti ML; Herlyn M
Carcinog Compr Surv; 1989; 11():369-86. PubMed ID: 2646021
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
